CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
   
  The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and up-to-date therapeutic strategies, which in turn facilitates optimal patient care.
  
  
  LEARNING OBJECTIVES
  • Describe the biologic rationale for and emerging roles of novel and approved antibody-drug conjugates — alone and in combination with chemotherapy — in the treatment of Hodgkin lymphoma and other CD30- or CD22-positive lymphomas.
  • Integrate recent clinical research findings with proteasome inhibitors and immunomodulatory agents into the development of individualized induction and maintenance treatment strategies for patients with multiple myeloma.
  • Compare and contrast the benefits and risks of approved first- and second-generation tyrosine kinase inhibitors as therapeutic options for patients with chronic myeloid leukemia.
  • Develop an understanding of the mechanisms of action and emerging efficacy and side-effect data with JAK2 inhibitors in myelofibrosis in order to inform patients about options in and outside of the research setting.
  • Counsel patients with follicular lymphoma about recent advances in induction and maintenance systemic treatment.
  • Recall ongoing clinical trials evaluating innovative investigational approaches for diverse hematologic cancers, and consent or refer appropriate patients for study participation.
  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
   
  CREDIT DESIGNATION STATEMENT
   
  Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  
  HOW TO USE THIS CME ACTIVITY
   
  This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/HOU212/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as relevant full-text articles, abstracts, trial information and other web resources.
  
  
  CONTENT VALIDATION AND DISCLOSURES
   
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
   
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Cheson — Advisory Committee: Celgene Corporation, Cephalon Inc, Gilead Sciences Inc, Mundipharma International Limited, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi; Consulting Agreements: Celgene Corporation, Cephalon Inc, Genentech BioOncology, Mundipharma International Limited. Dr Jakubowiak — Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation. Dr Jabbour — Consulting Agreements: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr Rummel — Advisory Committee: Amgen Inc, Celgene Corporation, Mundipharma International Limited, Roche Laboratories Inc; Consulting Agreement: Mundipharma International Limited.
  
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
  
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  
  This activity is supported by educational grants from Allos Therapeutics, Genentech BioOncology/Biogen Idec, Incyte Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
  
  Hardware/Software Requirements:
  A high-speed Internet connection  
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
   
  Last review date: October 2012
  Expiration date: October 2013
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.